A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer.

ABSTRACT: Epithelial ovarian cancer (EOC) generally responds well to oncological treatments, but the eventual development of a refractory disease is a major clinical problem. Presently, there are no prognostic blood-based biomarkers for the stratification of EOC patients at the time of diagnosis. We set out to assess and validate the prognostic utility of a novel two-lipid signature, as the lipidome is known to be markedly aberrant in EOC patients. The study consisted of 499 women with histologically confirmed EOC that were prospectively recruited at the university hospitals in Turku (Finland) and Charité (Berlin, Germany). Lipidomic screening by tandem liquid chromatography-mass spectrometry (LC-MS/MS) was performed for all baseline serum samples of these patients, and additionally for 20 patients

SUBMITTER: Salminen L 

PROVIDER: S-EPMC8067677 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature